Abstract
This report reviews some of the new studies regarding new hormonal contraceptive formulations (e.g., Yaz, Qlaira(®), extended-cycle or continuous combined contraceptives, subcutaneous depot medroxyprogesterone acetate, and ulipristal acetate as an emergency contraceptive). Recent data on the relationship between hormonal contraceptive use and bone health are also reviewed.